This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. *(currently amended)* A method of manufacturing a medicament for the treatment of viral infections, comprising the step of providing a compound of formula



(I)

a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof,

wherein-$a^1$=$a^2$-$a^3$=$a^4$- represents a bivalent radical of formula

-CH=CH-CH=CH- (a-1);

-N=CH-CH=CH- (a-2);

-CH=N-CH=CH- (a-3);

-CH=CH-N=CH- (a-4); or

-CH=CH-CH=N- (a-5);

wherein each hydrogen atom in the radicals (a-1), (a-2), (a-3), (a-4) and (a-5) may optionally be replaced by halo, $C_{1-6}$alkyl, nitro, amino, hydroxy, $C_{1-6}$alkyloxy, polyhalo $C_{1-6}$alkyl, carboxyl, amino$C_{1-6}$alkyl, mono- or di($C_{1-4}$alkyl)amino$C_{1-6}$alkyl, $C_{1-6}$alkyloxycarbonyl, hydroxy$C_{1-6}$alkyl, or a radical of formula




wherein =Z is =O, =CH-C(=O)-$NR^{5a}R^{5b}$, =$CH_2$, =CH-$C_{1-6}$alkyl, =N-OH or =N-O-$C_{1-6}$alkyl;

Q is a radical of formula



(b-1) (b-2) (b-3) (b-4)

(b-5) (b-6) (b-7) (b-8)

wherein Alk is $C_{1-6}$alkanediyl;

$Y^1$ is a bivalent radical of formula $-NR^2-$ or $-CH(NR^2R^4)-$;

$X^1$ is $NR^4$, S, S(=O), $S(=O)_2$, O, $CH_2$, C(=O), $C(=CH_2)$, CH(OH), $CH(CH_3)$, $CH(OCH_3)$, $CH(SCH_3)$, $CH(NR^{5a}R^{5b})$, $CH_2$-$NR^4$ or $NR^4$-$CH_2$;

$X^2$ is a direct bond, $CH_2$, C(=O), $NR^4$, $C_{1-4}$alkyl-$NR^4$, $NR^4$-$C_{1-4}$alkyl;

t is 2, 3, 4 or 5;

u is 1, 2, 3, 4 or 5;

v is 2 or 3; and

whereby each hydrogen atom in Alk and the carbocycles and the heterocycles defined in radicals (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8) may optionally be replaced by $R^3$; with the proviso that when $R^3$ is hydroxy or $C_{1-6}$alkyloxy, then $R^3$ can not replace a hydrogen atom in the α position relative to a nitrogen atom;

G is a direct bond or $C_{1-10}$alkanediyl;

$R^1$ is a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrrolyl, furanyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, and isothiazolyl; and each heterocycle may optionally be substituted with 1 or where possible more, such as 2, 3 or 4, substituents selected from halo, hydroxy, amino, cyano, carboxy, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, $C_{1-6}$alkylthio, $C_{1-6}$alkyloxy$C_{1-6}$alkyl, aryl, aryl$C_{1-6}$alkyl, aryl$C_{1-6}$alkyloxy, hydroxy$C_{1-6}$alkyl, mono-or di($C_{1-6}$alkyl)amino, mono-or di($C_{1-6}$alkyl)amino$C_{1-6}$alkyl, polyhalo$C_{1-6}$alkyl, $C_{1-6}$alkylcarbonylamino, $C_{1-6}$alkyl-$SO_2$-$NR^{5c}$-, aryl-$SO_2$-$NR^{5c}$-, $C_{1-6}$alkyloxycarbonyl, -C(=O)-$NR^{5c}R^{5d}$, HO(-$CH_2$-$CH_2$-

O)$_n$-, halo(-$CH_2$-$CH_2$-O)$_n$-, $C_{1-6}$alkyloxy(-$CH_2$-$CH_2$-O)$_n$-, aryl$C_{1-6}$alkyloxy(-$CH_2$-$CH_2$-O)$_n$- and mono-or di($C_{1-6}$alkyl)amino(-$CH_2$-$CH_2$-O)$_n$-;

each n independently is 1, 2, 3 or 4;

$R^2$ is hydrogen, formyl, $C_{1-6}$alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, $C_{3-7}$cycloalkyl substituted with $N(R^6)_2$, or $C_{1-10}$alkyl substituted with $N(R^6)_2$ and optionally with a second, third or fourth substituent selected from amino, hydroxy, $C_{3-7}$cycloalkyl, $C_{2-5}$alkanediyl, piperidinyl, mono-or di($C_{1-6}$alkyl)amino, $C_{1-6}$alkyloxycarbonylamino, aryl and aryloxy;

$R^3$ is hydrogen, hydroxy, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, aryl$C_{1-6}$alkyl or aryl$C_{1-6}$alkyloxy;

$R^4$ is hydrogen, $C_{1-6}$alkyl or aryl$C_{1-6}$alkyl;

$R^{5a}$, $R^{5b}$, $R^{5c}$ and $R^{5d}$ each independently are hydrogen or $C_{1-6}$alkyl; or

$R^{5a}$ and $R^{5b}$, or $R^{5c}$ and $R^{5d}$ taken together form a bivalent radical of formula -$(CH_2)_s$- wherein s is 4 or 5;

$R^6$ is hydrogen, $C_{1-4}$alkyl, formyl, hydroxy$C_{1-6}$alkyl, $C_{1-6}$alkylcarbonyl or $C_{1-6}$alkyloxycarbonyl;

aryl is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, $C_{1-6}$alkyl, hydroxy$C_{1-6}$alkyl, polyhalo $C_{1-6}$alkyl, and $C_{1-6}$alkyloxy; **and**

Het is pyridyl, pyrimidinyl, pyrazinyl, **or** pyridazinyl.

2. *(currently amended)* A compound of formula (I')



(I)

a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof, wherein -$a^1$=$a^2$-$a^3$=$a^4$- represents a radical of formula

-CH=CH-CH=CH- (a-1);

-N=CH-CH=CH- (a-2);

-CH=N-CH=CH- (a-3);

-CH=CH-N=CH- (a-4); or

-CH=CH-CH=N- (a-5);

wherein each hydrogen atom in the radicals (a-1), (a-2), (a-3), (a-4) and (a-5) may optionally be replaced by halo, $C_{1-6}$alkyl, nitro, amino, hydroxy, $C_{1-6}$alkyloxy, polyhalo$C_{1-6}$alkyl, carboxyl, amino$C_{1-6}$alkyl, mono- or di($C_{1-4}$alkyl)amino$C_{1-6}$alkyl, $C_{1-6}$alkyloxycarbonyl, hydroxy$C_{1-6}$alkyl, or a radical of formula




wherein =Z is =O, =CH-C(=O)-$NR^{5a}R^{5b}$, =$CH_2$, =CH-$C_{1-6}$alkyl, =N-OH or =N-O-$C_{1-6}$alkyl;

Q is a radical of formula




(b-1) (b-2) (b-3) (b-4)




(b-5) (b-6) (b-7) (b-8)

wherein Alk is $C_{1-6}$alkanediyl;

$Y^1$ is a bivalent radical of formula –$NR^2$- or –$CH(NR^2R^4)$-;

$X^1$ is $NR^4$, S, S(=O), $S(=O)_2$, O, $CH_2$, C(=O), $C(=CH_2)$, CH(OH), $CH(CH_3)$, $CH(OCH_3)$, $CH(SCH_3)$, $CH(NR^{5a}R^{5b})$, $CH_2$-$NR^4$ or $NR^4$-$CH_2$;

$X^2$ is a direct bond, $CH_2$, C(=O), $NR^4$, $C_{1-4}$alkyl-$NR^4$, $NR^4$-$C_{1-4}$alkyl;

t is 2, 3, 4 or 5;

u is 1, 2, 3, 4 or 5;

v is 2 or 3; and

whereby each hydrogen atom in Alk and the carbocycles and the heterocycles defined in radicals (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8) may optionally be replaced by $R^3$;

with the proviso that when $R^3$ is hydroxy or $C_{1-6}$alkyloxy, then $R^3$ can not replace a hydrogen atom in the α position relative to a nitrogen atom;

G is a direct bond or $C_{1-10}$alkanediyl;

$R^1$ is a monocyclic heterocycle selected from pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrrolyl, imidazolyl and pyrazolyl; and each heterocycle may optionally be substituted with 1 or where possible more, such as 2, 3 or 4, substituents selected from halo, hydroxy, amino, cyano, carboxy, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, $C_{1-6}$alkylthio, $C_{1-6}$alkyloxy$C_{1-6}$alkyl, aryl, aryl$C_{1-6}$alkyl, aryl$C_{1-6}$alkyloxy, hydroxy$C_{1-6}$alkyl, mono- or di($C_{1-6}$alkyl)amino, mono-or di($C_{1-6}$alkyl)amino$C_{1-6}$alkyl, polyhalo$C_{1-6}$alkyl, $C_{1-6}$alkylcarbonylamino, $C_{1-6}$alkyl-$SO_2$-$NR^{5c}$-, aryl-$SO_2$-$NR^{5c}$-, $C_{1-6}$alkyloxycarbonyl, -C(=O)-$NR^{5c}R^{5d}$, HO(-$CH_2$-$CH_2$-O)$_n$-, halo(-$CH_2$-$CH_2$-O)$_n$-, $C_{1-6}$alkyloxy(-$CH_2$-$CH_2$-O)$_n$-, aryl$C_{1-6}$alkyloxy(-$CH_2$-$CH_2$-O)$_n$- and mono-or di($C_{1-6}$alkyl)amino(-$CH_2$-$CH_2$-O)$_n$-;

each n independently is 1, 2, 3 or 4;

$R^2$ is hydrogen, formyl, pyrrolidinyl, piperidinyl, homopiperidinyl, $C_{3-7}$cycloalkyl substituted with $N(R^6)_2$, or $C_{1-10}$alkyl substituted with $N(R^6)_2$ and optionally with a second, third or fourth substituent selected from amino, hydroxy, $C_{3-7}$cycloalkyl, $C_{2-5}$alkanediyl, piperidinyl, mono-or di($C_{1-6}$alkyl)amino, $C_{1-6}$alkyloxycarbonylamino, aryl and aryloxy;

$R^3$ is hydrogen, hydroxy, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy, aryl$C_{1-6}$alkyl or aryl $C_{1-6}$alkyloxy;

$R^4$ is hydrogen, $C_{1-6}$alkyl or aryl$C_{1-6}$alkyl;

$R^{5a}$, $R^{5b}$, $R^{5c}$ and $R^{5d}$ each independently are hydrogen or $C_{1-6}$alkyl; or

$R^{5a}$ and $R^{5b}$, or $R^{5c}$ and $R^{5d}$ taken together form a bivalent radical of formula -$(CH_2)_s$- wherein s is 4 or 5;

$R^6$ is hydrogen, $C_{1-4}$alkyl, formyl, hydroxy$C_{1-6}$alkyl, $C_{1-6}$alkylcarbonyl or $C_{1-6}$alkyloxycarbonyl;

aryl is phenyl or phenyl substituted with 1 or more, such as 2, 3 or 4, substituents selected from halo, hydroxy, $C_{1-6}$alkyl, hydroxy$C_{1-6}$alkyl, polyhalo$C_{1-6}$alkyl, and $C_{1-6}$alkyloxy;

provided that when G is methylene, and $R^1$ is 2-pyridyl, 3-pyridyl, 6-methyl-2-pyridyl, 2-pyrazinyl or 5-methyl-imidazol-4-yl, and $-a^1=a^2-a^3=a^4-$ is $-CH=CH-CH=CH-$ or $-N=CH-CH=CH-$, then Q is other than


; 
; 
;


; 
; **or**



3. *(previously amended)* A compound as claimed in claim 2, wherein:

when Q is 

wherein $X^1$ is $NR^4$, O, S, S(=O), $S(=O)_2$, $CH_2$, C(=O), $C(=CH_2)$ or $CH(CH_3)$, then $R^1$ is other than pyridyl, pyridyl substituted with $C_{1-6}$alkyl, pyrimidinyl, pyrazinyl, imidazolyl and imidazolyl substituted with $C_{1-6}$alkyl.

4. *(previously amended)* A compound as claimed in claim 2, wherein:

when Q is 

wherein $X^1$ is $NR^4$, O, S, S(=O), $S(=O)_2$, $CH_2$, C(=O), $C(=CH_2)$ or $CH(CH_3)$, then $R^1$ is other than pyridyl, pyridyl substituted with $C_{1-6}$alkyl, pyridyl substituted with 1 or 2 $C_{1-6}$alkyloxy, pyrazinyl, pyrrolyl, pyrrolyl substituted with $C_{1-6}$alkyl, imidazolyl and imidazolyl substituted with $C_{1-6}$alkyl.

5. *(previously amended)* A compound as claimed in claim 2, wherein:

when Q is 

wherein $X^1$ is $NR^4$, O, S, S(=O), $S(=O)_2$, $CH_2$, C(=O), $C(=CH_2)$ or $CH(CH_3)$, then $R^1$ is other than pyridyl, pyridyl substituted with $C_{1-6}$alkyl, pyrimidinyl, pyrazinyl, imidazolyl and imidazolyl substituted with $C_{1-6}$alkyl.

6. *(previously amended)* A compound as claimed in claim 2, wherein:

when Q is 

then $R^1$ is other than pyridyl, pyrimidinyl, pyrazinyl, imidazolyl and imidazolyl substituted with $C_{1-6}$alkyl.

7. *(previously amended)* A compound as claimed in claim 2, wherein:

when Q is 

wherein $X^2$ is $CH_2$ or a direct bond, then $R^1$ is other than pyridyl, pyridyl substituted with $C_{1-6}$alkyl, pyrimidinyl, pyrazinyl, imidazolyl and imidazolyl substituted with $C_{1-6}$alkyl.

8. *(previously amended)* A compound as claimed in claim 2, wherein the compound is:

(±)-2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-7-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride monohydrate;

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl-3-pyridinol;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(1,4-dimethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazol-2-amine monohydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-amine;

(±)-2-[[2-[(3-amino-2-hydroxypropyl)amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[[3-(2-ethoxyethoxy)-6-methyl-2-pyridinyl]methyl]-1H-benzimidazol-2-amine tetrahydrochloride dihydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(2-chloro-1,4-dimethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazol-2-amine;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-chloro-1-[(2-chloro-1,4-dimethyl-1H-imidazol-5-yl)methyl]-1H-benzimidazol-2-amine;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-6-methyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-amine;

(±)-N-[1-(2-aminopropyl)-4-piperidinyl]-1-[(3,5,6-trimethylpyrazinyl)methyl]-1H-benzimidazol-2-amine tetrahydrochloride trihydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(3,5,6-trimethylpyrazinyl)methyl]-1H-benzimidazol-2-amine;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[[3-(2-chloroethoxy)-6-methyl-2-pyridinyl]methyl]-1H-benzimidazol-2-amine trihydrochloride dihydrate;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[3-amino-2-pyridinyl)methyl]-1H-benzimidazol-2-amine tetrahydrochloride trihydrate;

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride;

(±)-2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-6-methyl-3-pyridinol;

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-6-chloro-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride 2-propanolate (1:1);

(±)-2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol;

(±)-2-[[2-[[1-(2-aminopropyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride trihydrate;

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-7-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride dihydrate;

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-6-bromo-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride;

2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride monohydrate;

(±)-2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol;

(±)-N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-4-methyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-benzimidazol-2-amine;

a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof.

9. *( currently amended)* A compound ~~as claimed in claim 2~~, wherein the compound is: 2-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-5-chloro-7-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol tetrahydrochloride tetrahydrate;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2,4-dimethyl-5-oxazolyl)methyl]-1H-benzimidazol-2-amine;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2,5-dimethyl-4-oxazolyl)methyl]-1H-benzimidazol-2-amine trihydrochloride monohydrate;

4-[[3-[[5-(methoxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridine-2-yl]methyl]-1-piperidineetanamine;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(5-methyl-3-isoxazolyl)methyl]-1H-benzimidazol-2-amine trihydrochloride monohydrate;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-5-oxazolyl)methyl]-1H-benzimidazol-2-amine monohydrate;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-5-oxazolyl)methyl]-1H-benzimidazol-2-amine trihydrochloride monohydrate;

N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(2,4-dimethyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-amine;

4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazineethanamine;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-(4-thiazolylmethyl)-1H-benzimidazol-2-amine;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-1H-benzimidazol-2-amine trihydrochloride;

5-[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino-1H-benzimidazol-1-yl]methyl-2-oxazolemethanol tetrahydrochloride dihydrate;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(3-methyl-5-isoxazolyl)methyl]-1H-benzimidazol-2-amine trihydrochloride monohydrate;

4-[[1-[[2-(dimethylamino)-4-thiazolyl]methyl]-1H-benzimidazol-2-yl]methyl]-1-piperidineethanamine tetrahydrochloride monohydrate 2-propanolate (1:1);

ethyl 5-[[2-[[1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-4-piperidinyl]amino]-1H-benzimidazol-1-yl]methyl]-2-methyl-4-oxazolecarboxylate;

4-[[1-[(2-methyl-4-thiazolyl)methyl]-1H-benzimidazol-2-yl]methyl]-1-piperidineethanamine;

N-[1-(2-aminoethyl)-4-piperidinyl]-1-[(2-methyl-3-furanyl)methyl]-1H-benzimidazol-2-amine;

ethyl 4-[[3-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-7-methyl-3H-imidazo[4,5-b]pyridine-2-yl]amino]-1-piperidinecarboxylate;

1,1-dimethylethyl 4-[[1-[[3-[2-(dimethylamino)ethoxy]-6-methyl-2-pyridinyl]methyl]-1H-benzimidazol-2-yl]amino-1-piperidinecarboxylate;

ethyl 4-[[1-[(3-amino-2-pyridinyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate;

N-[1-(6-methyl-2-pyridinyl)-1H-benzimidazol-2-yl]-1-(3-pyridinylcarbonyl)-4-piperidinamine;

a prodrug, *N*-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof.

10. *(previously amended)* A method of using as a medicine a compound as claimed in any one of claims 2 to 9.

11. *(previously amended)* A method of manufacturing a medicament for the treatment of viral infections, comprising the step of providing the compound as claimed in claim 9.

12. *(previously amended)* The method of claim 1 or 11, wherein said viral infection is a respiratory syncytial virus infection.

13. *(previously amended)* A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 2 to 9.

14. *(previously amended)* A process of preparing a composition as claimed in claim 13, comprising the step of intimately mixing said carrier with said compound.

15. *(previously amended)* A process of preparing a compound as claimed in claim 2, comprising at least one step selected from the group consisting of:

a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III)




with $R^1$, G, Q and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $W_1$ being a suitable leaving group, in the presence of a suitable base and in a suitable reaction-inert solvent;

b) deprotecting an intermediate of formula (IV)




with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, H-$Q_1$ being defined as Q according to claim 2 provided that $R^2$ or at least one $R^6$ substituent is hydrogen, and P being a protective group;

c) deprotecting and reducing an intermediate of formula (IV-a)




(IV-a) (I'-a)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, H-$Q_1$ being defined as Q according to claim 2 provided that $R^2$ or at least one $R^6$ substituent is hydrogen, $Q_{1a}$(CH=CH) being defined as $Q_1$ provided that $Q_1$ comprises an unsaturated bond, and P being a protective group;

d) deprotecting an intermediate of formula (V)




(V) (I'-a-1)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $H_2N$-$Q_2$ being defined as Q according to claim 2 provided that both $R^6$ substituents are hydrogen or $R^2$ and $R^4$ are both hydrogen;

e) deprotecting an intermediate of formula (VI)




(VI) (I'-a-1)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $H_2N$-$Q_2$ being defined as Q according to claim 2 provided that both $R^6$ substituents are hydrogen or $R^2$ and $R^4$ are both hydrogen, and P being a protective group;

f) deprotecting an intermediate of formula (VII) or (VIII)



(VII) (I'-a-2)



(VIII) (I'-a-1-1)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, H-$Q_1$'(OH) being defined as Q according to claim 2 provided that $R^2$ or at least one $R^6$ substituent is hydrogen and provided that Q comprises a hydroxy moiety, $H_2N$-$Q_2$'(OH) being defined as Q according to claim 2 provided that both $R^6$ substituents are hydrogen or $R^2$ and $R^4$ are both hydrogen and provided that Q comprises a hydroxy moiety, and P being a protective group;

g) amination of an intermediate of formula (IX)




(IX) (I'-a-1-2)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $H_2N$-$Q_3H$ being defined as Q according to claim 2 provided that both $R^6$ substituents are hydrogen or $R^2$ and $R^4$ are both hydrogen, and the carbon adjacent to the nitrogen carrying the $R^6$, or $R^2$ and $R^4$ substituents contains at least one hydrogen, in the presence of a suitable amination reagent;

h) reducing an intermediate of formula (X)




(X) (I'-a-1-3)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $H_2N-CH_2-Q_4$ being defined as Q according to claim 2 provided that Q comprises a $-CH_2-NH_2$ moiety, in the presence of a suitable reducing agent;

i) reducing an intermediate of formula (X-a)




(X-a) (I'-a-1-3-1)

with G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, $H_2N-CH_2-Q_4$ being defined as Q according to claim 2 provided that Q comprises a $-CH_2-NH_2$ moiety, and $R^{1'}$ being defined as $R^1$ according to claim 2 provided that it comprises at least one substituent, in the presence of a suitable reducing agent and suitable solvent;

j) amination of an intermediate of formula (XI)



(XI) (I'-a-1-3-2)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $H_2N-CH_2-CHOH-CH_2-Q_4$, being defined as Q according to claim 2 provided that Q comprises a $CH_2-CHOH-CH_2-NH_2$ moiety, in the presence of a suitable amination reagent;

k) reacting an intermediate of formula (XII) with formic acid, formamide and ammonia



(XII) (I'-b)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and H-C(=O)-$Q_1$ being defined as Q according to claim 2 provided that $R^2$ or at least one $R^6$ substituent is formyl;

l) amination of an intermediate of formula (XIII) by reaction with an intermediate of formula (XIV)



(XIII) (XIV) (I'-c)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $R^{2a}$-NH-$HQ_5$ being defined as Q according to claim 2 provided that $R^2$ is other than hydrogen and is represented by $R^{2a}$, $R^4$ is hydrogen, and the carbon atom adjacent to the nitrogen atom carrying the $R^2$ and $R^4$ substituents, carries also at least one hydrogen atom, in the presence of a suitable reducing agent;

m) reducing an intermediate of formula (XV)



(XV) (I'-c-1)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $(R^6)_2N$-[$(C_{1-9}$alkyl)$CH_2OH$]-NH-$HQ_5$ being defined as Q according to claim 2 provided that $R^2$ is other than hydrogen and is represented by $C_{1-10}$alkyl substituted with $N(R_6)_2$ and with hydroxy, and the carbon atom carrying the hydroxy, carries also two hydrogen atoms, and provided that $R^4$ is hydrogen, and the carbon atom adjacent to the nitrogen atom

carrying the $R^2$ and $R^4$ substituents, carries also at least one hydrogen atom, with a suitable reducing agent;

n) deprotecting an intermediate of formula (XVI), (XVI-a) or (XVI-b)



(XVI) (I'-d)

(XVI-a) (I'-d-1)

(XVI-b) (I'-d-2)

with G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $H-Q_1$ being defined as Q according to claim 2 provided that $R^2$ or at least one $R^6$ substituent is hydrogen, and $R^{1a}$-(A-O-H)$_w$, $R^{1a'}$-(A-O-H)$_2$ and $R^{1a''}$-(A-O-H)$_3$ being defined as $R^1$ according to claim 2 provided that $R^1$ is substituted with hydroxy, hydroxy$C_{1-6}$alkyl, or HO(-$CH_2$-$CH_2$-O)$_n$-, with w being an integer from 1 to 4 and P or $P_1$ being a suitable protecting group, with a suitable acid;

o) amination of an intermediate of formula (XVII)



(XVII) (XVIII) (I'-e)

with $R^1$, G, $-a^1=a^2-a^3=a^4-$, Alk, $X^1$ $R^2$ and $R^4$ defined as in claim 2, in the presence of a suitable amination agent; and

p) amination of an intermediate of formula (XIX)



(XIX) (XX) (I'-p)

with $R^1$, G, and $-a^1=a^2-a^3=a^4-$ defined as in claim 2, and $Q_6N$-$CH_2$-$C_{1-3}$alkyl-$NR^4$ being defined as Q according to claim 2 provided that in the definition of Q, $X^2$ is $C_{2-4}$alkyl-$NR^4$, in the presence of a suitable amination agent.

16. *(previously amended)* A product, comprising:

(a) a first compound as claimed in any one of claims 2 to 9; and

(b) a second antiviral compound,

wherein said first compound and said second compound are simultaneously, separately or sequentially used in the treatment or the prevention of viral infections.

17. *(previously amended)* A pharmaceutical composition, comprising:

(a) a pharmaceutically acceptable carrier; and

(b) as active ingredients:

i. a first compound as claimed in any one of claims 2 to 9; and

ii. a second antiviral compound.

18. *(previously added)* The process of claim 15, further comprising the step of converting compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into a therapeutically active non-toxic acid addition salt by treatment with an acid.

19. *(previously added)* The process of claim 15, further comprising the step of converting compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into a therapeutically active non-toxic base addition salt by treatment with alkali.

20. *(previously added)* The process of claim 15, further comprising the step of converting the acid addition salt form of compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into the free base by treatment with alkali.

21. *(previously added)* The process of claim 15, further comprising the step of converting the base addition salt form of compound of formula (I'), stereochemically isomeric forms, metal complexes, quaternary amines or *N*-oxide forms thereof, into the free acid by treatment with acid.

22. *(new)* The process of claim 15, further comprising the step of converting said compound of formula (I'), stereochemically isomeric form, metal complex, quaternary amine or *N*-oxide form thereof, into a different form of compound of formula (I'), stereochemically isomeric form, metal complex, quaternary amine or *N*-oxide form thereof